Butyrate ameliorates alcoholic fatty liver disease via reducing endotoxemia and inhibiting liver gasdermin D-mediated pyroptosis

Ting Zhang; Jun Li; Cui-Ping Liu; Man Guo; Chen-Lin Gao; Lu-Ping Zhou; Yang Long; Yong Xu

doi:10.21037/atm-21-2158

Butyrate ameliorates alcoholic fatty liver disease via reducing endotoxemia and inhibiting liver gasdermin D-mediated pyroptosis

Ann Transl Med. 2021 May;9(10):873. doi: 10.21037/atm-21-2158.

Authors

Ting Zhang^{1

2}, Jun Li², Cui-Ping Liu¹, Man Guo¹, Chen-Lin Gao¹, Lu-Ping Zhou¹, Yang Long^{1

3}, Yong Xu^{1

3

4}

Affiliations

¹ Department of Endocrinology and Metabolism, Affiliated Hospital of Southwest Medical University, Luzhou, China.
² Institute of Life Sciences, Chongqing Medical University, Chongqing, China.
³ Cardiovascular and Metabolic Diseases Key Laboratory of Luzhou, Luzhou, China.
⁴ Sichuan Clinical Research Center for Nephropathy, Luzhou, China.

Abstract

Background: Alcoholic fatty liver disease (AFLD) is characterized by hepatic steatosis and carries an elevated risk of cirrhosis and hepatocellular carcinoma. However, the mechanism of AFLD has not been elucidated thoroughly, and there are still no efficient therapies in clinic. Notably, butyrate, one kind of short-chain fatty acids produced by gut microbiota, has been shown to improve methionine-choline-deficient diet-induced non-alcoholic steatohepatitis. And our previous study found that butyrate ameliorated endotoxemia in db/db mice. In this study, we aimed to explore the role of butyrate in the development of AFLD.

Methods: C57BL/6 mice were treated with saline (normal control), alcohol with or without butyrate by gavage for 6 months. AFLD was evaluated by the levels of serum alcohol, aspartate aminotransferase (AST), alanine transaminase (ALT), triglyceride (TG) and intrahepatic TG. And the histology and inflammation in liver and colon were analyzed using hematoxylin-eosin (H&E) staining, immunohistochemistry and western blot. In addition, gut microbiota composition was analyzed using the V3-V4 regions of the bacterial 16S ribosomal RNA gene by sequence. Furthermore, we performed in vitro experiment to verify the role of butyrate in hepatocyte by western blot and transmission electron microscopy.

Results: We found that butyrate ameliorated alcohol-induced hepatic steatosis and inflammation. Furthermore, chronic alcohol feeding induced dysbiosis and dysfunction of the gut microbiota, disrupted the intestinal barrier, and increased serum endotoxin levels. Meanwhile, butyrate improved the intestinal barrier disruption and endotoxemia induced by alcohol, but did not significantly alleviate the microbiome dysfunction. Mechanistically, butyrate ameliorated AFLD by inhibiting gasdermin D (GSDMD)-mediated pyroptosis.

Conclusions: In summary, we found butyrate ameliorated alcoholic fatty liver by down-regulating GSDMD-mediated pyroptosis. We speculate that butyrate improves AFLD mainly by maintaining intestinal barrier function and alleviating gut leakage. These findings suggest that butyrate may have the potential to serve as a novel treatment for AFLD.

Keywords: Alcoholic fatty liver disease (AFLD); butyrate; endotoxin; pyroptosis.